PRA Health Sciences (PRAH) Tops Q4 EPS by 4c, Offers FY Guidance

PRA Health Sciences (NASDAQ: PRAH) reported Q4 EPS of $1.31, $0.04 better than the analyst estimate of $1.27. Revenue for the quarter came in at $729.6 million versus the consensus estimate of $741.59 million.

GUIDANCE:

PRA Health Sciences sees FY2019 EPS of $4.93-$5.08, versus the consensus of $4.93. PRA Health Sciences sees FY2019 revenue of $3.09-3.2 billion, versus the consensus of $3.14 billion.

For earnings history and earnings-related data on PRA Health Sciences (PRAH) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Allison Transmission (ALSN) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY24 Revenue Guidance
• The First Of Long Island (FLIC) Misses Q1 EPS by 3c